NLRP3 Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes Patients

Table 2

The association of NLRP3 rs35829419 with the risk for macro- and microvascular complications in type 2 diabetes patients.

T2D complications	All patients				Male patients
	CC; (%)	CA + AA; (%)	OR (95% CI)		CC; (%)	CA + AA; (%)	OR (95% CI)
Macrovascular	35 (21.9)	11 (52.4)	3.93 (1.54–10.00)	0.004	21 (23.1)	8 (57.1)	4.44 (1.39–14.25)	0.012
PAOD	7 (4.4)	3 (14.3)	3.64 (0.86–15.34)	0.078	4 (4.4)	3 (21.4)	5.93 (1.17–30.06)	0.032
ICD	12 (7.5)	4 (19.1)	2.90 (0.84–10.01)	0.092	9 (9.9)	3 (21.4)	2.48 (0.58–10.60)	0.219
MI	25 (15.6)	7 (33.3)	2.70 (0.99–7.36)	0.052	14 (15.4)	5 (35.7)	3.06 (0.89–10.48)	0.076
Microvascular	28 (17.5)	6 (28.6)	1.89 (0.67–5.29)	0.228	17 (18.7)	6 (42.9)	3.26 (1.00–10.65)	0.050
End-stage kidney failure	20 (12.5)	5 (23.8)	2.19 (0.72–6.63)	0.166	11 (12.1)	5 (35.7)	4.04 (1.14–14.27)	0.030
Retinopathy	12 (7.5)	3 (14.3)	2.06 (0.53–7.98)	0.298	9 (9.9)	1 (7.1)	0.70 (0.08–6.00)	0.746
Neuropathy	12 (7.5)	1 (4.8)	0.61 (0.08–4.97)	0.646	8 (8.8)	3 (21.4)	2.83 (0.65–12.29)	0.165

PAOD: peripheral arterial occlusive disease; 16 (8.85%) ICD: ischemic cerebrovascular disease; MI: myocardial infarction.